モノクローナル抗体の世界市場

モノクローナル抗体の世界市場は2030年までに2,668億米ドルに達する見込み

2023年に1,688億米ドルと推定されるモノクローナル抗体の世界市場は、2030年には2,668億米ドルに達し、分析期間2023-2030年のCAGRは6.8%で成長すると予測されます。本レポートで分析したセグメントの1つであるヒト由来モノクローナル抗体は、CAGR 8.2%を記録し、分析期間終了時には1,052億米ドルに達すると予測されます。ヒト化モノクローナル抗体セグメントの成長率は、分析期間中CAGR 6.9%と推定されます。

米国市場は454億米ドルと推定、中国はCAGR 11.2%で成長予測

米国のモノクローナル抗体市場は2023年に454億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR 11.2%を牽引し、2030年には予測市場規模621億米ドルに達すると予測されます。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と7.1%と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

モノクローナル抗体-主要動向と促進要因

免疫システムの重要な構成要素である抗体は、病原体の侵入に反応してBリンパ球によって産生されるY字型のタンパク質です。この分子は免疫防御において極めて重要な役割を果たしており、それぞれの抗体は特定の抗原を認識し結合するように調整されています。モノクローナル抗体（mAbs）は、バイオ医薬品業界において重要なセクターであり、特に腫瘍学、自己免疫疾患、感染症の領域において、急速な成長と治療への多大な貢献を特徴としています。この成長はいくつかの重要な要因によってもたらされ、治療モノクローナル抗体の将来を形作る新たな動向に支えられています。モノクローナル抗体の将来は、科学と技術の継続的な進歩が市場を前進させるため、有望視されています。研究が分子レベルで疾患に対する理解を深めるにつれ、mAbsは医療においてますます重要な役割を果たすようになると予想されます。さらに、医薬品開発パイプラインにAIと機械学習を統合することで、モノクローナル抗体の特異性と機能性が強化され、副作用の少ないより効果的な治療法につながる可能性があります。

より優れた細胞株工学や強化されたタンパク質発現システムを含むバイオテクノロジー手法の絶え間ない進化は、モノクローナル抗体の開発と生産を著しく改善しました。これらの進歩により、mAbsの有効性、安全性、安定性が向上し、臨床での使用がより魅力的なものとなっています。がん、関節リウマチ、多発性硬化症などの慢性疾患の世界の有病率は上昇しており、モノクローナル抗体による治療は特に有効であることが証明されています。このような疾患罹患率の増加は、mAbsが提供できる標的治療に対する需要を押し上げています。全体として、モノクローナル抗体市場は継続的な成長と革新の態勢にあり、ヘルスケアの成果に大きな影響を与え、その開発と商業化に携わる製薬企業に大きな機会を提供することが期待されています。

次世代抗体技術の登場は、治療法の展望を大きく豊かにしました。一本鎖可変フラグメント（scFv）、ナノボディ、二重特異性抗体、Fc改変抗体、抗体バイオシミラー、抗体模倣体、抗体薬物複合体などの革新はすべて、医療におけるmAbsの可能性を広げてきました。今日、抗体工学は進化し、単一ドメイン抗体（VHH）、単鎖可変フラグメント（scFv）、抗原結合フラグメント（Fab）など、従来のY字型構造を超える様々な形式が含まれるようになった。これらの技術革新は、抗体の特異性を高め、免疫原性を低下させ、薬物動態を改善することにより、治療における抗体の有用性を拡大します。遺伝子工学や突然変異誘発によって抗体を改変できるようになったことで、融合抗体や、免疫反応を高め、組織への浸透を改善し、循環半減期を延長するように設計されたその他の新規構築物の創製への道が開かれました。これらの能力により、モノクローナル抗体は、特にがんや自己免疫疾患などの複雑な疾患の治療において、現代の治療戦略の要として確固たる地位を築いています。

調査対象企業の例（全123社）

• Abbott Diagnostics, Inc.-Core Laboratory
• AbbVie, Inc.
• Amgen, Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis International AG

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Monoclonal Antibodies Market to Reach US$266.8 Billion by 2030

The global market for Monoclonal Antibodies estimated at US$168.8 Billion in the year 2023, is expected to reach US$266.8 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2023-2030. Human-sourced Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$105.2 Billion by the end of the analysis period. Growth in the Humanized Monoclonal Antibodies segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$45.4 Billion While China is Forecast to Grow at 11.2% CAGR

The Monoclonal Antibodies market in the U.S. is estimated at US$45.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$62.1 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Monoclonal Antibodies  - Key Trends and Drivers

Antibodies, crucial components of the immune system, are Y-shaped proteins produced by B lymphocytes in response to pathogen invasion. These molecules play a pivotal role in immunological defense, with each antibody tailored to recognize and bind to specific antigens, a characteristic that underpins their therapeutic potential in modern medicine. Monoclonal antibodies (mAbs) represent a significant sector in the biopharmaceutical industry, characterized by rapid growth and substantial contributions to medical treatments, particularly in the areas of oncology, autoimmune diseases, and infectious diseases. This growth is driven by several key factors and supported by emerging trends that are shaping the future of therapeutic monoclonal antibodies. The future of monoclonal antibodies looks promising with continued advancements in science and technology driving the market forward. As research deepens our understanding of diseases at the molecular level, mAbs are expected to play an increasingly vital role in medicine. Moreover, the integration of AI and machine learning in drug development pipelines is likely to enhance the specificity and functionality of monoclonal antibodies, potentially leading to more effective therapies with fewer side effects.

The continuous evolution of biotechnological methods, including better cell line engineering and enhanced protein expression systems, has significantly improved the development and production of monoclonal antibodies. These advancements have increased the efficacy, safety, and stability of mAbs, making them more attractive for clinical use. There is a rising global prevalence of chronic diseases such as cancer, rheumatoid arthritis, and multiple sclerosis, where treatment with monoclonal antibodies has proven particularly effective. This increase in disease incidence has driven demand for targeted therapies that mAbs can provide. Overall, the monoclonal antibodies market is poised for continued growth and innovation, promising significant impacts on healthcare outcomes and offering substantial opportunities for pharmaceutical companies engaged in their development and commercialization.

The advent of next-generation antibody technologies has significantly enriched the therapeutic landscape. Innovations such as single-chain variable fragments (scFvs), nanobodies, bispecific antibodies, Fc-engineered antibodies, antibody biosimilars, antibody mimetics, and antibody-drug conjugates have all expanded the potential of mAbs in medicine. Today, antibody engineering has evolved to include a variety of formats beyond the traditional Y-shaped structure, such as single-domain antibodies (VHH), single-chain variable fragments (scFv), and antigen-binding fragments (Fab). These innovations expand the utility of antibodies in therapeutics by enhancing their specificity, reducing immunogenicity, and improving pharmacokinetics. The ability to modify antibodies through genetic engineering and mutagenesis has paved the way for the creation of fusion antibodies and other novel constructs designed to elicit enhanced immune responses, improve tissue penetration, and extend circulation half-lives. These capabilities have solidified monoclonal antibodies as a cornerstone of modern therapeutic strategies, particularly in treating complex diseases such as cancers and autoimmune disorders.

Select Competitors (Total 123 Featured) -

• Abbott Diagnostics, Inc. - Core Laboratory
• AbbVie, Inc.
• Amgen, Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis International AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Monoclonal Antibodies - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Chronic Diseases Strengthens Business Case for Monoclonal Antibody Therapies
  • Growing Awareness of the Benefits of Monoclonal Antibody Therapies Drives Adoption Across Various Medical Fields
  • Advances in Biotechnology Propel Growth of Monoclonal Antibodies Market
  • Increasing Adoption of Personalized Medicine Expands Addressable Market Opportunity for Monoclonal Antibodies
  • Growth in Cancer Treatment Generates Demand for Targeted Monoclonal Antibody Solutions
  • Innovations in Antibody Engineering Technology Spurs Market Growth for Monoclonal Antibodies
  • Focus on Immunotherapy Throws the Spotlight on Monoclonal Antibody Advancements
  • Expansion of Biopharmaceutical Manufacturing Sustains Growth in Monoclonal Antibodies Market
  • Integration of AI and Machine Learning in Drug Development Enhances Monoclonal Antibody Discovery
  • Technological Developments in Antibody-Drug Conjugates Propel Market Expansion for Monoclonal Antibodies
  • Emphasis on Reducing Treatment Costs Drives Adoption of Biosimilar Monoclonal Antibodies
  • Growth in Autoimmune Disease Treatment Spurs Use of Monoclonal Antibody Therapies
  • Adoption of Monoclonal Antibodies in Infectious Disease Management Expands Addressable Market Opportunity
  • Focus on Enhancing Efficacy and Safety Throws the Spotlight on Advanced Monoclonal Antibody Research
  • Increasing Use of Monoclonal Antibodies in Pediatric Care Accelerates Demand for Specialized Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Humanized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Humanized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Humanized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Chimeric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Chimeric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Chimeric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Murine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Murine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Murine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Autoimmune diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Autoimmune diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Autoimmune diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Infectious diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Infectious diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 27: World 16-Year Perspective for Infectious diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 30: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 33: World 16-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 35: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 36: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 37: World Monoclonal Antibodies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• JAPAN
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• CHINA
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: China 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• EUROPE
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Monoclonal Antibodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• FRANCE
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: France 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: France 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• GERMANY
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Monoclonal Antibodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• INDIA
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: India 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: India 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: India 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Monoclonal Antibodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Monoclonal Antibodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
• AFRICA
  • Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION